Actively Recruiting
Safety Evaluation of Sotatercept With Standard Treatment for Adults With Pulmonary Arterial Hypertension in India
Led by Merck Sharp & Dohme LLC · Updated on 2026-11-04
30
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying pulmonary arterial hypertension PAH, a condition where blood vessels in the lungs become thick and narrow, leading to high blood pressure in the lungs and heart strain. The study focuses on whether sotatercept, a biological medicine, can be safely given alongside standard PAH treatments to people in India who have difficulty breathing and being active due to PAH symptoms. This is a Phase 4, open-label, single-arm study evaluating safety and tolerability. Participants will receive sotatercept by subcutaneous injection every 21 days, starting at a dose of 0.3 mgkg and aiming to reach 0.7 mgkg, alongside their usual PAH medications. Background therapies may include one or a combination of approved PAH drugs such as Endothelin Receptor Antagonists, Phosphodiesterase Type 5 Inhibitors, soluble guanylate cyclase stimulators, or prostacyclin analogues. The treatment period extends up to approximately 37 weeks. During the study, participants will be monitored for adverse events and any reasons to stop the study drug, with follow-up lasting up to about 37 weeks. Safety assessments will track the number of participants experiencing side effects and those discontinuing treatment due to such events. The study aims to provide detailed safety information on sotatercept when used with standard PAH therapies.
CONDITIONS
Brief Title
A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here